MIRD Pamphlet No. 30: MIRDfit-A Tool for Fitting of Biodistribution Time-Activity Data for Internal Dosimetry.

Autor:	Carter LM; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; carterl1@mskcc.org., Ocampo Ramos JC; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York., Schuerrle SB; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany; and., Marquis H; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York., Lassmann M; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany; and., Bolch WE; J. Crayton Pruitt Department of Nuclear Engineering, University of Florida, Gainesville, Florida., Kesner AL; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Nov 01; Vol. 65 (11), pp. 1808-1814. Date of Electronic Publication: 2024 Nov 01.
DOI:	10.2967/jnumed.124.268011
Abstrakt:	In nuclear medicine, estimating the number of radioactive decays that occur in a source organ per unit administered activity of a radiopharmaceutical (i.e., the time-integrated activity coefficient [TIAC]) is an essential task within the internal dosimetry workflow. TIAC estimation is commonly derived by least-squares fitting of various exponential models to organ time-activity data (radiopharmaceutical biodistribution). Rarely, however, are methods used to objectively determine the model that best characterizes the data. Additionally, the uncertainty associated with the resultant TIAC is generally not evaluated. As part of the MIRDsoft initiative, MIRDfit has been developed to offer a biodistribution fitting software solution that provides the following essential features and advantages for internal dose assessment: nuclear medicine-appropriate fit functions; objective metrics for guiding best-fit selection; TIAC uncertainty calculation; quality control and data archiving; integration with MIRDcalc software for dose calculation; and a user-friendly Excel-based interface. For demonstration and comparative validation of MIRDfit's performance, TIACs were derived from serial imaging studies involving 18 F-FDG and 177 Lu-DOTATATE using MIRDfit. These TIACs were then compared with TIAC estimates obtained using other software. In most cases, the TIACs agreed within approximately 10% between MIRDfit and the other software. MIRDfit has been endorsed by the MIRD Committee of the Society of Nuclear Medicine and Molecular Imaging and has been integrated into the MIRDsoft suite of free dosimetry software; it is available for download at no user cost (https://mirdsoft.org/). (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu